Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 2/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19024861 | 0.86 | L3MBTL1 (0.59) | CYP4F2CYP4A11TSHRALDH1A1LMNA | |
| SCHEMBL11509273 | 0.85 | TDP1 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23287934 | 0.84 | IDO1 (0.47) | CYP4F2CYP4A11TSHRALDH1A1LMNA | |
| SCHEMBL10020494 | 0.84 | FKBP1A (0.52) | CYP4F2CYP4A11TSHRALDH1A1LMNA | |
| SCHEMBL9350223 | 0.84 | CYP4F2 (0.46) | CYP4F2CYP4A11TSHRALDH1A1LMNA | |
| SCHEMBL22652835 | 0.84 | CYP4F2 (0.46) | CYP4F2CYP4A11TSHRALDH1A1LMNA | |
| SCHEMBL3183513 | 0.84 | TSHR (0.68) | TSHRALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL5361353 | 0.83 | KDM4E (0.58) | CYP4F2CYP4A11TSHRALDH1A1LMNA | |
| SCHEMBL11512222 | 0.83 | KDM4E (0.45) | CYP4F2CYP4A11TSHRALDH1A1LMNA | |
| SCHEMBL7525162 | 0.83 | ALDH1A1 (0.64) | ALDH1A1LMNATDP1L3MBTL1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117865782-A | Method for preparing monophenol chemicals by catalyzing lignin depolymerization with zeolite-like imidazole ester framework material derivatives | 华南理工大学 | 2024-04-12 | — | — | CN | claimed |
| US-7183281-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-27 | — | — | US | claimed |
| US-7074783-B2 | Sulfonylbenzodiazepinone acetamides as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2006-07-11 | — | — | US | claimed |
| EP-1549622-A1 | SULFONYLBENZODIAZEPINONE ACETAMIDES AS BRADYKININ ANTAGONISTS | Elian Pharmaceuticals Inc. (US) | 2005-07-06 | — | — | EP | claimed |
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | claimed |
| US-20040138208-A1 | Sulfonylbenzodiazepinone acetamides as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-15 | — | — | US | claimed |
| WO-2004033436-A1 | SULFONYLBENZODIAZEPINONE ACETAMIDES AS BRADYKININ ANTAGONISTS | ELAN PHARMACEUTICALS INC (US) | 2004-04-22 | — | — | WO | claimed |
| CN-118401537-A | Pyridoxal-5-phosphate (P5P) analogues | 加美生物研究公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-117865782-A | Method for preparing monophenol chemicals by catalyzing lignin depolymerization with zeolite-like imidazole ester framework material derivatives | 华南理工大学 | 2024-04-12 | — | — | CN | disclosed |
| CN-115611735-A | Method for preparing p-hydroxy-benzene propionate by depolymerizing lignin under catalysis of nickel loaded on layered hierarchical pore molecular sieve | 华南理工大学 | 2023-01-17 | — | — | CN | disclosed |
| CN-101967096-B | 3-[4-(alkoxy) phenyl] propionate compound and preparation method and application thereof | UNIV SICHUAN | 2013-05-22 | — | — | CN | disclosed |
| CN-101967096-A | 3-[4-(alkoxy) phenyl] propionate compound and preparation method and application thereof | UNIV SICHUAN | 2011-02-09 | — | — | CN | disclosed |
| US-7635775-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| EP-1501807-A1 | SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS | Elan Pharmaceuticals, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004098590-A1 | 4-BROMO-5- (2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (1-(AMINOCARBONYL) ETH-1-YL) AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| US-20040138208-A1 | Sulfonylbenzodiazepinone acetamides as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-15 | — | — | US | disclosed |
| WO-2004033436-A1 | SULFONYLBENZODIAZEPINONE ACETAMIDES AS BRADYKININ ANTAGONISTS | ELAN PHARMACEUTICALS INC (US) | 2004-04-22 | — | — | WO | disclosed |
| WO-2003093245-A1 | SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS | ELAN PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| WO-2002015691-A1 | USE FOR CONIFER SAPLING PROTECTION AGAINST INSECT ATTACK | ROBIGUS AB (SE) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | BDKRB2, BDKRB1, PDXK | CA12 2479/4885CA1 1006/4885CA2 384/4885 |
| US-20040138208-A1 | Sulfonylbenzodiazepinone acetamides as bradykinin antagonists | BDKRB1, BDKRB2, HRH2 | CA12 2983/4885CA1 1803/4885CA2 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.